Skip to content

Efficacy of Different Frequencies of Pelvic Floor Myofascial Release on Female Pelvic Floor Myofascial Pain Syndrome: A Randomized Controlled Trial.

Efficacy of Different Frequencies of Pelvic Floor Myofascial Release on Female Pelvic Floor Myofascial Pain Syndrome: A Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107828
Enrollment
Unknown
Registered
2025-08-19
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Floor Myofascial Pain Syndrome

Interventions

High-frequency group:Receiving pelvic floor myofascial release therapy twice a week for 6 weeks, totaling 12 treatments.
Low-frequency group:Receiving pelvic floor myofascial release therapy once a week for 6 weeks, totaling 6 treatments.
Control group:Receiving standardized biofeedback electrical stimulation therapy twice a week, totaling 12 treatments.

Sponsors

Jiaxing University Affiliated Women and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Female, aged 18 to 65 years; 2. Clinically diagnosed with Pelvic Floor Myofascial Pain Syndrome (PFMPS) according to the following diagnostic criteria: A. Myofascial trigger points (MTrPs) identified through pelvic floor muscle palpation, standardized vaginal examination by an experienced clinician; B. Pelvic floor muscle tenderness and/or tension/spasm detected; C. Exclusion of other obvious organic or neurological causes of pain; 3. Clean lochia with no active vaginal bleeding; 4. Willing to voluntarily sign informed consent and comply with treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Active pelvic infections (such as vaginitis, cervicitis, pelvic inflammatory disease, etc.); 2. History or suspicion of pelvic or urogenital malignancy; 3. Pregnancy or plans to become pregnant during the study period; 4. Pelvic pain caused by other uncontrolled diseases (such as active endometriosis); 5. Presence of pelvic implants or other contraindications for electrical stimulation or microwave therapy (e.g., pacemakers); 6. Severe mental or cognitive disorders that significantly affect adherence to the study or outcome evaluation.

Design outcomes

Primary

MeasureTime frame
MTrPs-triggered pain Visual Analog Scale (VAS);Number of MTrPs;Surface Electromyography (sEMG) Glazer Score;

Secondary

MeasureTime frame
Oxford Muscle Strength Score (0-5 points);Pelvic Floor Distress Inventory (PFDI-20);Pelvic Floor Impact Questionnaire (PFIQ-7);Female Sexual Function Index (FSFI);Patient Global Impression of Improvement (PGI-I);

Countries

China

Contacts

Public ContactChangna Wei

Jiaxing University Affiliated Women and Children Hospital

544631360@qq.com+86 182 6738 2732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026